Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Vivus reaches agreement with FDA on Qnexa NDA

Sep. 19, 2011

Catabasis Pharmaceuticals identifies new NF-kappa-B activation inhibitors

Sep. 19, 2011

Ono Pharmaceutical secures new Japanese approval for Glactiv

Sep. 19, 2011

Top-line phase I data on VRS-859 for type 2 diabetes

Sep. 19, 2011

TIGEM describes HDAd-based gene therapy for primary hyperoxaluria type 1 / News in Context

Sep. 19, 2011

Researchers at Merck & Co. disclose new AMPK activators

Sep. 16, 2011

Preclinical and phase I data presented on insulin sensitizer LIM-0705

Sep. 16, 2011

Randomized, double-blind trial assesses LY-2189265 as monotherapy for type 2 diabetes

Sep. 15, 2011

Repros completes enrollment in three ongoing Androxal trials

Sep. 15, 2011

Lexicon's antidiabetes candidate LX-4211 affects multiple parameters of glycemic control

Sep. 14, 2011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 6, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
Novartis to pay $1.5B for Myricx Bio and its novel ADC payloads
BioWorld
Novartis AG is to pay $1.1 billion up front to acquire Myricx Bio Ltd., a preclinical-stage antibody-drug conjugate (ADC) specialist that is advancing a novel and...